​

Zentalis Pharmaceuticals (ZNTL) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

ZNTL Stock Forecast

Zentalis Pharmaceuticals (ZNTL) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $7.67, with a high of $10.00 and a low of $5.00. This represents a 247.06% increase from the last price of $2.21.

$1 $2 $3 $4 $5 $6 $7 $8 $9 $10 High: $10 Avg: $7.67 Low: $5 Last Closed Price: $2.21

ZNTL Stock Rating

Zentalis Pharmaceuticals stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (66.67%), 4 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 4 8 0 Strong Sell Sell Hold Buy Strong Buy

ZNTL Price Target Upside V Benchmarks

TypeNameUpside
StockZentalis Pharmaceuticals247.06%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts125
Avg Price Target$8.00$6.50$7.00
Last Closing Price$2.21$2.21$2.21
Upside/Downside261.99%194.12%216.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26-55--10
Sep, 26-45--9
Aug, 26-55--10
Jul, 26-45--9
Jun, 26-35--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 05, 2026Leerink Partners$8.00$2.52217.46%261.99%
Aug 07, 2026Morgan Stanley$5.00$4.2816.82%126.24%
May 22, 2026Andrew FeinH.C. Wainwright$10.00$4.14141.55%352.49%
Apr 10, 2026Guggenheim$10.00$6.1462.87%352.49%
Nov 11, 2025Andrew BerensLeerink Partners$2.00$1.3251.52%-9.50%
Jun 18, 2024Akash TewariJefferies$6.00$4.3139.21%171.49%
Jun 18, 2024Matthew HarrisonMorgan Stanley$8.00$4.1493.24%261.99%
Jun 18, 2024Bradley CaninoStifel Nicolaus$10.00$5.3985.53%352.49%
Jun 18, 2024Robert DriscollWedbush$4.00$5.70-29.82%81.00%
May 07, 2024Bradley CaninoStifel Nicolaus$32.00$12.43157.44%1347.96%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 19, 2026H.C. WainwrightBuyBuyhold
Sep 15, 2026William BlairOutperforminitialise
Jul 23, 2026Rodman & RenshawBuyinitialise
May 22, 2026H.C. WainwrightBuyBuyhold
Apr 10, 2026GuggenheimBuyBuyhold
Nov 11, 2025Leerink PartnersMarket PerformMarket Performhold
Jan 29, 2025OppenheimerOutperformOutperformhold
Sep 16, 2024Cowen & Co.BuyBuyhold
Sep 16, 2024OppenheimerOutperformOutperformhold
Aug 12, 2024WedbushHoldNeutralupgrade

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.47$-2.33$-1.91---
Avg Forecast$-4.41$-2.52$-2.90$-2.57$-2.33$-1.21
High Forecast$-3.93$-2.35$-2.40$-1.00$-1.57$-1.21
Low Forecast$-5.16$-2.72$-3.35$-3.51$-2.95$-1.21
Surprise %1.36%-7.54%-34.14%---

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$67.42M----
Avg Forecast-$40.62M$2.67M$23.02M$42.76M$175.34M
High Forecast-$40.98M$2.67M$23.02M$42.76M$175.34M
Low Forecast-$40.54M$2.67M$23.02M$42.76M$175.34M
Surprise %-65.99%----

Net Income Forecast

$-350M $-290M $-230M $-170M $-110M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-292.19M$-165.84M$-137.06M---
Avg Forecast$-292.19M$-165.94M$-187.97M$-147.51M$-147.68M$-79.01M
High Forecast$-257.01M$-153.99M$-156.69M$-65.13M$-102.55M$-79.01M
Low Forecast$-337.33M$-177.89M$-219.24M$-229.88M$-192.82M$-79.01M
Surprise %--0.06%-27.08%---

ZNTL Forecast FAQ

Is Zentalis Pharmaceuticals stock a buy?

Zentalis Pharmaceuticals stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Zentalis Pharmaceuticals is a favorable investment for most analysts.

What is Zentalis Pharmaceuticals's price target?

Zentalis Pharmaceuticals's price target, set by 12 Wall Street analysts, averages $7.67 over the next 12 months. The price target range spans from $5 at the low end to $10 at the high end, suggesting a potential 247.06% change from the previous closing price of $2.21.

How does Zentalis Pharmaceuticals stock forecast compare to its benchmarks?

Zentalis Pharmaceuticals's stock forecast shows a 247.06% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Zentalis Pharmaceuticals over the past three months?

  • October 2026: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 0% Strong Buy, 44.44% Buy, 55.56% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 0% Strong Buy, 50.00% Buy, 50.00% Hold, 0% Sell, 0% Strong Sell.

What is Zentalis Pharmaceuticals’s EPS forecast?

Zentalis Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.57, marking a 34.55% increase from the reported $-1.91 in 2025. Estimates for the following years are $-2.33 in 2027, and $-1.21 in 2028.

What is Zentalis Pharmaceuticals’s revenue forecast?

Zentalis Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $23.02M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $42.76M, and $175.34M for 2028.

What is Zentalis Pharmaceuticals’s net income forecast?

Zentalis Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-148M, representing an 7.62% increase from the reported $-137M in 2025. Projections indicate $-148M in 2027, and $-79.014M in 2028.